Results 211 to 220 of about 927,052 (258)
Some of the next articles are maybe not open access.
Clinical Efficacy and Safety of Anti-IL-17 Agents for the Treatment of Patients with Psoriasis
Immunotherapy, 2015To evaluate the therapeutic efficacy and safety of anti-IL-17 agents in the treatment of psoriasis, we performed a systemic review and meta-analysis of the relevant published clinical trials, collectively referred to as secukinumab, ixekizumab and brodalumab.
Yan, Chen +4 more
openaire +2 more sources
Psoriasis: Anti-IL-17-Inhibitor als Rescue-Therapie?
hautnah dermatologie, 2019In einer Subgruppenanalyse der Studien AMAGINE-2 und -3 wurde untersucht, wie gut Brodalumab bei Psoriasispatienten wirkt, wenn sie zuvor unzureichend auf Ustekinumab angesprochen hatten.
openaire +1 more source
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
American Journal of Clinical DermatologyInnovations in biologics are transforming the treatment of psoriatic diseases. The ability to target specific levels of immune activation provides a distinct advantage. Interleukin (IL)-17 inhibitors fall into this class of biologics, and they are effectively used to treat a spectrum of psoriatic diseases, such as psoriasis vulgaris and psoriatic ...
Dahyeon Kim +5 more
openaire +2 more sources
Maladie de Darier et anti IL 17
Annales de Dermatologie et de Vénéréologie - FMC, 2023M. Daude, S. Barbarot
openaire +1 more source
Side effects of Anti IL-17 A in the ENT domain
Laryngo-Rhino-Otologie, 2023Sebastian Kotz +3 more
openaire +1 more source
Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
Journal of drugs in dermatology : JDD, 2016Studies investigating the molecular basis of psoriasis have established the central roles of TNFa, interleukin (IL)-12, IL-22 and IL-23, and now there is increasing evidence that IL-17 plays a vital role in the complex pathophysiology of this disease. Preclinical and phase II studies of medications targeting IL-17 and its receptor have thus far proved ...
Benjamin, Farahnik +8 more
openaire +1 more source
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Annual Review of Immunology, 2022Matthew D Vesely, Lieping Chen
exaly
Anti IL-17 flared psoriasis in a patient on secukinumab
Dermatologic Therapy, 2017Claire Noell +3 more
openaire +1 more source
Adalimumab in drei Fällen von Anti‐IL‐17‐refraktärer Acrodermatitis continua Hallopeau
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023Zhenying Zhang +4 more
openaire +2 more sources